A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
出版年份 2013 全文链接
标题
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 17, Pages 3420-3427
出版商
American Society of Hematology
发表日期
2013-03-12
DOI
10.1182/blood-2012-12-473066
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CyBorD: stellar response rates in AL amyloidosis
- (2012) G. Merlini BLOOD
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
- (2011) J. E. Ward et al. BLOOD
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
- (2011) S. Madan et al. BLOOD
- Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis
- (2011) S O Schönland et al. BONE MARROW TRANSPLANTATION
- Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis
- (2011) A. D. Wechalekar et al. HAEMATOLOGICA
- Amyloidosis: Pathogenesis and New Therapeutic Options
- (2011) Giampaolo Merlini et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
- (2010) A. V. Kristen et al. BLOOD
- The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
- (2010) G. Palladini et al. BLOOD
- Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
- (2010) S. Dietrich et al. BLOOD
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
- (2010) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
- (2010) Karl Bodin et al. NATURE
- Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
- (2008) Giovanni Palladini et al. ANNALS OF HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started